Structural biology of complement receptors

The complement system plays crucial roles in a wide breadth of immune and inflammatory processes and is frequently cited as an etiological or aggravating factor in many human diseases, from asthma to cancer. Complement receptors encompass at least eight proteins from four structural classes, orchestrating complement-mediated humoral and cellular effector responses and coordinating the complex cross-talk between innate and adaptive immunity. The progressive increase in understanding of the structural features of the main complement factors, activated proteolytic fragments, and their assemblies have spurred a renewed interest in deciphering their receptor complexes. In this review, we describe what is currently known about the structural biology of the complement receptors and their complexes with natural agonists and pharmacological antagonists. We highlight the fundamental concepts and the gray areas where issues and problems have been identified, including current research gaps. We seek to offer guidance into the structural biology of the complement system as structural information underlies fundamental and therapeutic research endeavors. Finally, we also indicate what we believe are potential developments in the field.

[1]  V. Holers Complement therapeutics are coming of age in rheumatology , 2023, Nature Reviews Rheumatology.

[2]  Xi Cheng,et al.  Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins , 2023, Nature chemical biology.

[3]  C. Kemper,et al.  Complosome — the intracellular complement system , 2023, Nature Reviews Nephrology.

[4]  D. Fairlie,et al.  Ras-Related Protein Rab5a Regulates Complement C5a Receptor Trafficking, Chemotaxis, and Chemokine Secretion in Human Macrophages , 2023, Journal of Innate Immunity.

[5]  Xiaowen Tian,et al.  Mechanism of activation and biased signaling in complement receptor C5aR1 , 2023, Cell Research.

[6]  John D Lambris,et al.  Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery , 2023, American journal of hematology.

[7]  J. Paz,et al.  Complement: The Road Less Traveled. , 2023, Journal of immunology.

[8]  L. Roumenina,et al.  C3‐dependent effector functions of complement , 2022, Immunological reviews.

[9]  K. Ley,et al.  Structural Basis of β2 Integrin Inside—Out Activation , 2022, Cells.

[10]  A. Ruocco,et al.  The role of C5a-C5aR1 axis in bone pathophysiology: A mini-review , 2022, Frontiers in Cell and Developmental Biology.

[11]  J. McLellan,et al.  Structural basis for non-canonical integrin engagement by Bordetella adenylate cyclase toxin , 2022, Cell reports.

[12]  J. Köhl,et al.  Anaphylatoxins spark the flame in early autoimmunity , 2022, Frontiers in Immunology.

[13]  N. S. Laursen,et al.  Structural insights into the function-modulating effects of nanobody binding to the integrin receptor αMβ2 , 2022, The Journal of biological chemistry.

[14]  S. Rodríguez de Córdoba,et al.  The crystal structure of iC3b-CR3 αI reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor , 2022, Nature Communications.

[15]  C. Hoffmann,et al.  GPCR kinase knockout cells reveal the impact of individual GRKs on arrestin binding and GPCR regulation , 2022, Nature communications.

[16]  T. Woodruff,et al.  Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. , 2021, Journal of medicinal chemistry.

[17]  Stephen P. H. Alexander,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors , 2021, British journal of pharmacology.

[18]  S. Endow Faculty Opinions recommendation of Highly accurate protein structure prediction with AlphaFold. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[19]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[20]  A. Erdei,et al.  New aspects in the regulation of human B cell functions by complement receptors CR1, CR2, CR3 and CR4. , 2021, Immunology letters.

[21]  D. Ricklin,et al.  The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology , 2021, Frontiers in Immunology.

[22]  G. Varrassi,et al.  Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives , 2021, Biomedicines.

[23]  D. Hilger The role of structural dynamics in GPCR‐mediated signaling , 2021, The FEBS journal.

[24]  P. Proost,et al.  Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis , 2021, Frontiers in Cell and Developmental Biology.

[25]  Z. Bajtay Biologia Futura: stories about the functions of β2-integrins in human phagocytes , 2021, Biologia Futura.

[26]  T. Woodruff,et al.  Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors , 2021, bioRxiv.

[27]  D. Alsteens,et al.  Submolecular probing of the complement C5a receptor–ligand binding reveals a cooperative two-site binding mechanism , 2020, Communications biology.

[28]  Xu Han,et al.  Complement factor C4a does not activate protease‐activated receptor 1 (PAR1) or PAR4 on human platelets , 2020, Research and practice in thrombosis and haemostasis.

[29]  Ming-hui Zhao,et al.  The Complement C3a and C3a Receptor Pathway in Kidney Diseases , 2020, Frontiers in Immunology.

[30]  T. Woodruff,et al.  C5aR2 Activation Broadly Modulates the Signaling and Function of Primary Human Macrophages , 2020, The Journal of Immunology.

[31]  Xu Han,et al.  Complement factor C4a does not activate protease activated receptor 1 (PAR1) or PAR4 on human platelets , 2020, bioRxiv.

[32]  T. Woodruff,et al.  Emerging Insights into the Structure and Function of Complement C5a Receptors. , 2020, Trends in biochemical sciences.

[33]  T. Springer,et al.  Complement Receptor 3 Forms a Compact High-Affinity Complex with iC3b , 2020, The Journal of Immunology.

[34]  J. García-Nafría,et al.  Cryo-Electron Microscopy: Moving Beyond X-Ray Crystal Structures for Drug Receptors and Drug Development. , 2020, Annual review of pharmacology and toxicology.

[35]  E. Shakhnovich,et al.  Common activation mechanism of class A GPCRs , 2019, eLife.

[36]  M. Petzl-Erler,et al.  Complement Receptor 1 (CR1, CD35) Polymorphisms and Soluble CR1: A Proposed Anti-inflammatory Role to Quench the Fire of “Fogo Selvagem” Pemphigus Foliaceus , 2019, Front. Immunol..

[37]  Z. Mackey,et al.  CRIg plays an essential role in intravascular clearance of bloodborne parasites by interacting with complement , 2019, Proceedings of the National Academy of Sciences.

[38]  B. Morgan,et al.  Compendium of current complement therapeutics. , 2019, Molecular immunology.

[39]  B. Geisbrecht,et al.  The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1)1. , 2019, Seminars in immunology.

[40]  L. Hviid,et al.  Cerebral Plasmodium falciparum malaria: The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1‐based vaccines to prevent it , 2019, Immunological reviews.

[41]  M. T. B. Geller,et al.  Molecular , 2019, Modern Pathology.

[42]  You-Wen He,et al.  The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy , 2019, Front. Immunol..

[43]  A. Rosanas-Urgell,et al.  Complement Receptor 1 availability on red blood cell surface modulates Plasmodium vivax invasion of human reticulocytes , 2019, Scientific Reports.

[44]  S. Rodríguez de Córdoba,et al.  The Antimicrobials Anacardic Acid and Curcumin Are Not-Competitive Inhibitors of Gram-Positive Bacterial Pathogenic Glyceraldehyde-3-Phosphate Dehydrogenase by a Mechanism Unrelated to Human C5a Anaphylatoxin Binding , 2019, Front. Microbiol..

[45]  T. Woodruff,et al.  Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1 , 2019, The Journal of Biological Chemistry.

[46]  J. R. Regueiro,et al.  Lymphocyte integration of complement cues. , 2019, Seminars in cell & developmental biology.

[47]  T. Vorup-Jensen,et al.  Structural Immunology of Complement Receptors 3 and 4 , 2018, Front. Immunol..

[48]  Guohui Li,et al.  Intramembrane ionic protein–lipid interaction regulates integrin structure and function , 2018, PLoS biology.

[49]  M. Pirooznia,et al.  Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism , 2018, Nature Communications.

[50]  W. Weis,et al.  The Molecular Basis of G Protein-Coupled Receptor Activation. , 2018, Annual review of biochemistry.

[51]  M. van Lookeren Campagne,et al.  Pathogen clearance and immune adherence "revisited": Immuno-regulatory roles for CRIg. , 2018, Seminars in immunology.

[52]  K. Chung,et al.  Orthosteric and allosteric action of the C5a receptor antagonists , 2018, Nature Structural & Molecular Biology.

[53]  R. Wallis,et al.  Structure of the C1r–C1s interaction of the C1 complex of complement activation , 2018, Proceedings of the National Academy of Sciences.

[54]  G. Bottegoni,et al.  Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727 , 2018, Nature.

[55]  S. Gómez,et al.  Pathogens' toolbox to manipulate human complement. , 2017, Seminars in cell & developmental biology.

[56]  A. Erdei,et al.  Non-identical twins: Different faces of CR3 and CR4 in myeloid and lymphoid cells of mice and men. , 2017, Seminars in cell & developmental biology.

[57]  J. Köhl,et al.  Novel insights into the expression pattern of anaphylatoxin receptors in mice and men. , 2017, Molecular immunology.

[58]  Owen A. Hawksworth,et al.  New concepts on the therapeutic control of complement anaphylatoxin receptors. , 2017, Molecular immunology.

[59]  M. Garstka,et al.  The Controversial C5a Receptor C5aR2: Its Role in Health and Disease , 2017, Journal of immunology research.

[60]  G. Georgiou,et al.  IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions , 2017, Nature Immunology.

[61]  S. Muyldermans,et al.  Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity. , 2017, Immunobiology.

[62]  S. Rodríguez de Córdoba,et al.  Crystal Structure of Glyceraldehyde-3-Phosphate Dehydrogenase from the Gram-Positive Bacterial Pathogen A. vaginae, an Immunoevasive Factor that Interacts with the Human C5a Anaphylatoxin , 2017, Front. Microbiol..

[63]  T. Springer,et al.  Distinct recognition of complement iC3b by integrins αXβ2 and αMβ2 , 2017, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Michael Loran Dustin Complement Receptors in Myeloid Cell Adhesion and Phagocytosis , 2016, Microbiology spectrum.

[65]  J. Atkinson,et al.  Evolution of the complement system: from defense of the single cell to guardian of the intravascular space , 2016, Immunological reviews.

[66]  C. Floudas,et al.  Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling , 2016, Immunology and cell biology.

[67]  B. Schiøtt,et al.  Structural Basis for Simvastatin Competitive Antagonism of Complement Receptor 3* , 2016, The Journal of Biological Chemistry.

[68]  A. Sher,et al.  T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells , 2016, Science.

[69]  John D Lambris,et al.  New milestones ahead in complement-targeted therapy. , 2016, Seminars in immunology.

[70]  Todd H. Oakley,et al.  The last common ancestor of most bilaterian animals possessed at least 9 opsins , 2016, bioRxiv.

[71]  G. Bajic,et al.  The cationic peptide LL-37 binds Mac-1 (CD11b/CD18) with a low dissociation rate and promotes phagocytosis. , 2016, Biochimica et biophysica acta.

[72]  John D Lambris,et al.  Regulators of complement activity mediate inhibitory mechanisms through a common C3b‐binding mode , 2016, The EMBO journal.

[73]  T. Springer,et al.  Leukocyte integrin αLβ2 headpiece structures: The αI domain, the pocket for the internal ligand, and concerted movements of its loops , 2016, Proceedings of the National Academy of Sciences.

[74]  S. Barnum C4a: An Anaphylatoxin in Name Only , 2015, Journal of Innate Immunity.

[75]  A. Razim,et al.  Pathogens , 2014, Virulence.

[76]  P. Monk,et al.  C5a2 can modulate ERK1/2 signaling in macrophages via heteromer formation with C5a1 and β‐arrestin recruitment , 2014, Immunology and cell biology.

[77]  V. Holers Complement and its receptors: new insights into human disease. , 2014, Annual review of immunology.

[78]  J. Köhl,et al.  Novel roles for complement receptors in T cell regulation and beyond. , 2013, Molecular immunology.

[79]  T. Springer,et al.  An internal ligand-bound, metastable state of a leukocyte integrin, αXβ2 , 2013, The Journal of cell biology.

[80]  A. Cowman,et al.  Using Mutagenesis and Structural Biology to Map the Binding Site for the Plasmodium falciparum Merozoite Protein PfRh4 on the Human Immune Adherence Receptor* , 2013, The Journal of Biological Chemistry.

[81]  D. Fairlie,et al.  C5a, but not C5a‐des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2 , 2013, Immunology and cell biology.

[82]  Thomas Vorup-Jensen,et al.  Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3 , 2013, Proceedings of the National Academy of Sciences.

[83]  F. J. Fernández,et al.  Technologies to keep an eye on: alternative hosts for protein production in structural biology. , 2013, Current opinion in structural biology.

[84]  Bryan L. Roth,et al.  Structure of the human smoothened receptor bound to an antitumour agent , 2013, Nature.

[85]  M. Babu,et al.  Molecular signatures of G-protein-coupled receptors , 2013, Nature.

[86]  G. Larson,et al.  LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins. , 2013, Journal of proteome research.

[87]  H. Subramanian,et al.  Phosphorylation of C3a Receptor at Multiple Sites Mediates Desensitization, β-Arrestin-2 Recruitment and Inhibition of NF-κB Activity in Mast Cells , 2012, PloS one.

[88]  Danny W. Wilson,et al.  The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria , 2012, PloS one.

[89]  Michael Loran Dustin,et al.  Integrin inside-out signaling and the immunological synapse. , 2012, Current opinion in cell biology.

[90]  J. Xiong,et al.  Stable Coordination of the Inhibitory Ca2+ Ion at the Metal Ion-Dependent Adhesion Site in Integrin CD11b/CD18 by an Antibody-Derived Ligand Aspartate: Implications for Integrin Regulation and Structure-Based Drug Design , 2011, The Journal of Immunology.

[91]  H. Subramanian,et al.  Regulation of C3a Receptor Signaling in Human Mast Cells by G Protein Coupled Receptor Kinases , 2011, PloS one.

[92]  H. Subramanian,et al.  Distinct and Shared Roles of β-Arrestin-1 and β-Arrestin-2 on the Regulation of C3a Receptor Signaling in Human Mast Cells , 2011, PloS one.

[93]  D. Isenman,et al.  A Crystal Structure of the Complex Between Human Complement Receptor 2 and Its Ligand C3d , 2011, Science.

[94]  Yutaka Ito,et al.  Cellular structural biology. , 2010, Current opinion in structural biology.

[95]  Dave Richard,et al.  Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand , 2010, Proceedings of the National Academy of Sciences.

[96]  Can Xie,et al.  Structure of an integrin with an αI domain, complement receptor type 4 , 2010, The EMBO journal.

[97]  G. Zaman,et al.  C5a-Stimulated Recruitment of β-Arrestin2 to the Nonsignaling 7-Transmembrane Decoy Receptor C5L2 , 2009, Journal of biomolecular screening.

[98]  J. Köhl,et al.  The role of the anaphylatoxins in health and disease. , 2009, Molecular immunology.

[99]  J. Prechl,et al.  Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. , 2009, Molecular immunology.

[100]  John D Lambris,et al.  Structure of C3b-factor H and implications for host protection by complement regulators , 2009, Nature Immunology.

[101]  P. Monk,et al.  The human complement fragment receptor, C5L2, is a recycling decoy receptor , 2009, Molecular immunology.

[102]  M. Del Poeta,et al.  App1: An Antiphagocytic Protein That Binds to Complement Receptors 3 and 21 , 2009, The Journal of Immunology.

[103]  V. M. Holers,et al.  Solution structure of the complex formed between human complement C3d and full-length complement receptor type 2. , 2008, Journal of molecular biology.

[104]  R. Khera,et al.  Complement Receptor 1: Disease associations and therapeutic implications , 2008, Molecular Immunology.

[105]  F. Boulay,et al.  Complement Component 5a Receptor Oligomerization and Homologous Receptor Down-regulation* , 2008, Journal of Biological Chemistry.

[106]  M. Oppermann,et al.  Role of the carboxyl terminal di-leucine in phosphorylation and internalization of C5a receptor. , 2008, Biochimica et biophysica acta.

[107]  S. Hoffmann,et al.  Structural Insight into the Function of Myelin Basic Protein as a Ligand for Integrin αMβ21 , 2008, The Journal of Immunology.

[108]  John D. Lambris,et al.  Complement evasion by human pathogens , 2008, Nature Reviews Microbiology.

[109]  S. Perkins,et al.  The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands. , 2008, Journal of molecular biology.

[110]  John D Lambris,et al.  Complement-targeted therapeutics , 2007, Nature Biotechnology.

[111]  E. Mitchell,et al.  A Structural Hypothesis for the Transition between Bent and Extended Conformations of the Leukocyte β2 Integrins* , 2007, Journal of Biological Chemistry.

[112]  P. Monk,et al.  Function, structure and therapeutic potential of complement C5a receptors , 2007, British journal of pharmacology.

[113]  R. Roozendaal,et al.  Complement receptors CD21 and CD35 in humoral immunity , 2007, Immunological reviews.

[114]  M. van Lookeren Campagne,et al.  Macrophage complement receptors and pathogen clearance , 2007, Cellular microbiology.

[115]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[116]  G. Remuzzi,et al.  The interactive Factor H–atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models , 2007, Human mutation.

[117]  M. Oppermann,et al.  Dynamics of Protein Kinase C-mediated Phosphorylation of the Complement C5a Receptor on Serine 334* , 2007, Journal of Biological Chemistry.

[118]  G. Nikiforovich,et al.  A Comprehensive Structure-Function Map of the Intracellular Surface of the Human C5a Receptor , 2007, Journal of Biological Chemistry.

[119]  G. Nikiforovich,et al.  A Comprehensive Structure-Function Map of the Intracellular Surface of the Human C5a Receptor , 2007, Journal of Biological Chemistry.

[120]  Ian S Hagemann,et al.  Random Mutagenesis of the Complement Factor 5a (C5a) Receptor N Terminus Provides a Structural Constraint for C5a Docking* , 2006, Journal of Biological Chemistry.

[121]  A. Higginbottom,et al.  The Role of the N-terminal Domain of the Complement Fragment Receptor C5L2 in Ligand Binding* , 2006, Journal of Biological Chemistry.

[122]  P. Hass,et al.  Structure of C3b in complex with CRIg gives insights into regulation of complement activation , 2006, Nature.

[123]  H. E. Gilbert,et al.  The 15 SCR Flexible Extracellular Domains of Human Complement Receptor Type 2 can Mediate Multiple Ligand and Antigen Interactions , 2006 .

[124]  M. Kurrer,et al.  VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. , 2006, The Journal of clinical investigation.

[125]  Rengasamy Asokan,et al.  Characterization of Human Complement Receptor Type 2 (CR2/CD21) as a Receptor for IFN-α: A Potential Role in Systemic Lupus Erythematosus1 , 2006, The Journal of Immunology.

[126]  J. Klco,et al.  Genetic Analysis of the First and Third Extracellular Loops of the C5a Receptor Reveals an Essential WXFG Motif in the First Loop* , 2006, Journal of Biological Chemistry.

[127]  L. Diehl,et al.  CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens , 2006, Cell.

[128]  H. E. Gilbert,et al.  Extended flexible linker structures in the complement chimaeric conjugate CR2-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. , 2006, Journal of molecular biology.

[129]  M. Oppermann,et al.  G Protein-coupled Receptor Kinases Promote Phosphorylation and β-Arrestin-mediated Internalization of CCR5 Homo- and Hetero-oligomers* , 2005, Journal of Biological Chemistry.

[130]  J. Lescar,et al.  The Crystal Structure of the Plexin-Semaphorin-Integrin Domain/Hybrid Domain/I-EGF1 Segment from the Human Integrin β2 Subunit at 1.8-Å Resolution* , 2005, Journal of Biological Chemistry.

[131]  J. Parkinson,et al.  Large-scale modelling as a route to multiple surface comparisons of the CCP module family. , 2005, Protein engineering, design & selection : PEDS.

[132]  A. Higginbottom,et al.  Comparative Agonist/Antagonist Responses in Mutant Human C5a Receptors Define the Ligand Binding Site* , 2005, Journal of Biological Chemistry.

[133]  D. Soares,et al.  Complement Control Protein Modules in the Regulators of Complement Activation , 2005 .

[134]  J. Klco,et al.  Essential role for the second extracellular loop in C5a receptor activation , 2005, Nature Structural &Molecular Biology.

[135]  H. E. Gilbert,et al.  Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study. , 2005, Journal of molecular biology.

[136]  Rengasamy Asokan,et al.  Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. , 2005, Journal of molecular biology.

[137]  H. Miettinen,et al.  Different Endocytosis Pathways of the C5a Receptor and the N‐formyl Peptide Receptor , 2005, Traffic.

[138]  M. Barker,et al.  The use of membrane translocating peptides to identify sites of interaction between the C5a receptor and downstream effector proteins , 2004, Immunology.

[139]  E. Peerschke,et al.  cC1q-R (calreticulin) and gC1q-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection. , 2004, Molecular immunology.

[140]  K. Bromek,et al.  Backbone dynamics of complement control protein (CCP) modules reveals mobility in binding surfaces , 2004, Protein science : a publication of the Protein Society.

[141]  P. Taylor,et al.  Murine CD93 (C1qRp) Contributes to the Removal of Apoptotic Cells In Vivo but Is Not Required for C1q-Mediated Enhancement of Phagocytosis1 , 2004, The Journal of Immunology.

[142]  Somasekar Seshagiri,et al.  The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. , 2003, Genome research.

[143]  H. Choe,et al.  Sulfation of Tyrosine 174 in the Human C3a Receptor Is Essential for Binding of C3a Anaphylatoxin* , 2003, Journal of Biological Chemistry.

[144]  J. Klco,et al.  C5a Receptor Oligomerization , 2003, Journal of Biological Chemistry.

[145]  Kendall J Blumer,et al.  C5a Receptor Oligomerization , 2003, Journal of Biological Chemistry.

[146]  J. Krause,et al.  C5L2, a nonsignaling C5A binding protein. , 2003, Biochemistry.

[147]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[148]  M. Tardif,et al.  Direct binding of a fragment of the Wiskott-Aldrich syndrome protein to the C-terminal end of the anaphylatoxin C5a receptor. , 2003, The Biochemical journal.

[149]  R. Ames,et al.  Structure‐function studies of the C3a‐receptor: C‐terminal serine and threonine residues which influence receptor internalization and signaling , 2003, European journal of immunology.

[150]  L. Braun,et al.  Phosphorylation of Key Serine Residues Is Required for Internalization of the Complement 5a (C5a) Anaphylatoxin Receptor via a β-Arrestin, Dynamin, and Clathrin-dependent Pathway* , 2003, The Journal of Biological Chemistry.

[151]  J. Atkinson,et al.  Human complement receptor type 1 (CR1) binds to a major malarial adhesin. , 2002, Trends in molecular medicine.

[152]  R. Hynes,et al.  Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. , 2002, Molecular biology of the cell.

[153]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[154]  T. Stehle,et al.  The crystal structure of human CD21: Implications for Epstein–Barr virus and C3d binding , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[155]  P. Gasque,et al.  Human C1qRp Is Identical with CD93 and the mNI-11 Antigen But Does Not Bind C1q1 , 2002, The Journal of Immunology.

[156]  Stephen C. Blacklow,et al.  Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation , 2002, Nature Structural Biology.

[157]  K. Bromek,et al.  Structure of the C3b Binding Site of CR1 (CD35), the Immune Adherence Receptor , 2002, Cell.

[158]  P. Monk,et al.  The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg74 * , 2002, The Journal of Biological Chemistry.

[159]  H. E. Gilbert,et al.  Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. , 2001, Biochemical Society transactions.

[160]  T. Ugarova,et al.  The alternatively spliced αeC domain of human fibrinogen-420 is a novel ligand for leukocyte integrins αMβ2 and αXβ2 , 2001 .

[161]  B. Haribabu,et al.  Cutting Edge: Differential Regulation of Chemoattractant Receptor-Induced Degranulation and Chemokine Production by Receptor Phosphorylation1 , 2001, The Journal of Immunology.

[162]  S. Perkins,et al.  Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling. , 2001, Journal of molecular biology.

[163]  V. Michael Holers,et al.  Structure of Complement Receptor 2 in Complex with Its C3d Ligand , 2001, Science.

[164]  J. Kuhn,et al.  Sulfated Tyrosines Contribute to the Formation of the C5a Docking Site of the Human C5a Anaphylatoxin Receptor , 2001, The Journal of experimental medicine.

[165]  J Hinshelwood,et al.  Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. , 2001, Biochemistry.

[166]  J. Atkinson,et al.  Structure–function relationships of complement receptor type 1 , 2001, Immunological reviews.

[167]  J. Jensenius,et al.  Complement Receptor 1/Cd35 Is a Receptor for Mannan-Binding Lectin , 2000, The Journal of experimental medicine.

[168]  O. Lichtarge,et al.  Genetic Mapping of the Human C5a Receptor , 2000, The Journal of Biological Chemistry.

[169]  M. Enomoto,et al.  A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. , 2000, Molecular immunology.

[170]  M. Tardif,et al.  Human Complement 5a (C5a) Anaphylatoxin Receptor (CD88) Phosphorylation Sites and Their Specific Role in Receptor Phosphorylation and Attenuation of G Protein-mediated Responses , 2000, The Journal of Biological Chemistry.

[171]  W. Prodinger Complement receptor type two (CR2,CR21) , 1999, Immunologic research.

[172]  D. Hourcade,et al.  Decay Accelerating Activity of Complement Receptor Type 1 (CD35) , 1999, The Journal of Biological Chemistry.

[173]  Martin Oppermann,et al.  Ligand‐induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by G protein‐coupled receptor kinases , 1999, European journal of immunology.

[174]  O. Lichtarge,et al.  C5a Receptor Activation , 1999, The Journal of Biological Chemistry.

[175]  R. Ye,et al.  Role of the Second Extracellular Loop of Human C3a Receptor in Agonist Binding and Receptor Function* , 1999, The Journal of Biological Chemistry.

[176]  O. Götze,et al.  C3a(desArg) does not bind to and signal through the human C3a receptor. , 1999, Immunology letters.

[177]  H. Sarau,et al.  Chimeric Receptors of the Human C3a Receptor and C5a Receptor (CD88)* , 1999, The Journal of Biological Chemistry.

[178]  B. Finzel,et al.  Cation binding to the integrin CD11b I domain and activation model assessment. , 1998, Structure.

[179]  M. Grossmann,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[180]  W. Boyar,et al.  Residues 21–30 within the Extracellular N-terminal Region of the C5a Receptor Represent a Binding Domain for the C5a Anaphylatoxin* , 1998, The Journal of Biological Chemistry.

[181]  D. K. Smith,et al.  Sequence profiles of immunoglobulin and immunoglobulin-like domains. , 1997, Journal of molecular biology.

[182]  T. Hugli,et al.  Complement factors and their receptors. , 1997, Immunopharmacology.

[183]  F. Boulay,et al.  Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. , 1997, Journal of cell science.

[184]  L. Klickstein,et al.  Complement receptor type 1 (CR1, CD35) is a receptor for C1q. , 1997, Immunity.

[185]  P. Monk,et al.  The C terminus of the human C5a receptor (CD88) is required for normal ligand‐dependent receptor internalization , 1997, European journal of immunology.

[186]  Timothy A. Springer,et al.  Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain , 1997 .

[187]  R. Hertzberg,et al.  Molecular Cloning and Characterization of the Human Anaphylatoxin C3a Receptor* , 1996, The Journal of Biological Chemistry.

[188]  J. Köhl,et al.  Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U‐937 cells , 1996, European journal of immunology.

[189]  L. Brouchon,et al.  Identification of the Major Phosphorylation Sites in Human C5a Anaphylatoxin Receptor in Vivo(*) , 1995, The Journal of Biological Chemistry.

[190]  Y. Wong,et al.  The human chemoattractant complement C5a receptor inhibits cyclic AMP accumulation through Gi and Gz proteins. , 1995, Biochemical and biophysical research communications.

[191]  R. Liddington,et al.  Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18) , 1995, Cell.

[192]  L. Wennogle,et al.  Stabilization of C5a receptor–G‐protein interactions through ligand binding , 1994, Journal of cellular biochemistry.

[193]  J. Demartino,et al.  The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs. , 1994, The Journal of biological chemistry.

[194]  M. Diamond,et al.  The leukocyte integrin p150,95 (CD11c/CD18) as a receptor for iC3b. Activation by a heterologous beta subunit and localization of a ligand recognition site to the I domain. , 1994, Journal of immunology.

[195]  J. Demartino,et al.  Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[196]  F. Boulay,et al.  The NH2-terminal region of C5aR but not that of FPR is critical for both protein transport and ligand binding. , 1994, The Journal of biological chemistry.

[197]  D. Burton,et al.  Generation of chimeric C5a/formyl peptide receptors: towards the identification of the human C5a receptor binding site , 1994, European journal of immunology.

[198]  B. Eisfelder,et al.  Selective coupling of the human anaphylatoxin C5a receptor and α16 in human kidney 293 cells , 1993 .

[199]  M. Simon,et al.  Specific interactions of chemoattractant factor receptors with G-proteins. , 1993, The Journal of biological chemistry.

[200]  V. Vetvicka,et al.  CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions , 1993, Clinical and experimental immunology.

[201]  D. Montefiori,et al.  Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21) , 1993, Journal of virology.

[202]  M. Tardif,et al.  Agonist-dependent phosphorylation of N-formylpeptide and activation peptide from the fifth component of C (C5a) chemoattractant receptors in differentiated HL60 cells. , 1993, Journal of immunology.

[203]  M. Diamond,et al.  The I domain is a major recognition site on the leukocyte integrin Mac- 1 (CD11b/CD18) for four distinct adhesion ligands , 1993, The Journal of cell biology.

[204]  D. Montefiori,et al.  CD4‐independent binding of HIV‐1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody , 1992, Clinical and experimental immunology.

[205]  J. Bonnefoy,et al.  CD21 is a ligand for CD23 and regulates IgE production , 1992, Nature.

[206]  G. Carter,et al.  Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a. , 1992, Journal of medicinal chemistry.

[207]  G. Carter,et al.  Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. , 1991, Journal of medicinal chemistry.

[208]  M. Walport The third component of complement (current topics in microbiology and immunology) , 1991 .

[209]  S. Mathur,et al.  Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. , 1991, The EMBO journal.

[210]  M. Tardif,et al.  Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. , 1991, Biochemistry.

[211]  C. Gerard,et al.  The chemotactic receptor for human C5a anaphylatoxin , 1991, Nature.

[212]  I. Campbell,et al.  Secondary structure of a complement control protein module by two-dimensional 1H NMR. , 1991, Biochemistry.

[213]  M. Springer,et al.  Interaction between the C5a receptor and Gi in both the membrane-bound and detergent-solubilized states. , 1990, The Journal of biological chemistry.

[214]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[215]  B. Myones,et al.  Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. , 1990, The Journal of biological chemistry.

[216]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[217]  G. Nemerow,et al.  Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). , 1989, The Journal of biological chemistry.

[218]  D. Fearon,et al.  Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2 , 1989, The Journal of experimental medicine.

[219]  N. Hogg The leukocyte integrins. , 1989, Immunology today.

[220]  H. Kozono,et al.  C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. , 1988, Journal of immunology.

[221]  N. Hogg,et al.  Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. , 1988, The Journal of clinical investigation.

[222]  M. Frank,et al.  The complement fragment C3d facilitates phagocytosis by monocytes. , 1987, Immunology.

[223]  H. Kozono,et al.  Covalent association of C3b with C4b within C5 convertase of the classical complement pathway , 1987, The Journal of experimental medicine.

[224]  S. Wright,et al.  Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide , 1986, The Journal of experimental medicine.

[225]  G. Nemerow,et al.  Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2) , 1985, Journal of virology.

[226]  P. A. Biro,et al.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[227]  V. Nussenzweig,et al.  Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes , 1982, The Journal of experimental medicine.

[228]  H. Colten,et al.  Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer. , 1981, Journal of immunology.

[229]  T. Hugli,et al.  Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[230]  H. Müller-Eberhard,et al.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. , 1970, The Journal of clinical investigation.

[231]  R. A. Nelson The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. , 1953, Science.

[232]  M. Garstka,et al.  The Controversial C 5 a Receptor C 5 aR 2 : Its Role in Health and Disease , 2017 .

[233]  Francisco J Fernández,et al.  Choose a Suitable Expression Host: A Survey of Available Protein Production Platforms. , 2016, Advances in experimental medicine and biology.

[234]  M. Nonaka Evolution of the complement system. , 2014, Sub-cellular biochemistry.

[235]  A. Erdei,et al.  Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. , 2013, International immunology.

[236]  P. Monk,et al.  International Union of Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors , 2013 .

[237]  M. Stevenson of Basic , 2012 .

[238]  John D Lambris,et al.  Structure of complement fragment C 3 b – factor H and implications for host protection by complement regulators , 2009 .

[239]  H. E. Gilbert,et al.  The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions. , 2006, Journal of molecular biology.

[240]  P. Marche,et al.  Complement receptors and B lymphocytes. , 2004, Critical reviews in immunology.

[241]  R. Lefkowitz,et al.  Signalling: Seven-transmembrane receptors , 2002, Nature Reviews Molecular Cell Biology.

[242]  P. Gasque,et al.  Human C 1 qRp Is Identical with CD 93 and the mNI-11 Antigen But Does Not Bind C 1 q 1 , 2002 .

[243]  T. Ugarova,et al.  The alternatively spliced a E C domain of human fibrinogen-420 is a novel ligand for leukocyte integrins a M b 2 and a X b 2 , 2001 .

[244]  M. Carroll,et al.  The role of complement and complement receptors in induction and regulation of immunity. , 1998, Annual review of immunology.

[245]  J. Köhl,et al.  Site-Directed Mutagenesis of Conserved Charged Residues in the Helical Region of the Human C5a Receptor , 1996 .

[246]  J. Köhl,et al.  Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg2O6 determines high-affinity binding sites of C5a receptor. , 1996, European journal of biochemistry.

[247]  C. Gerard,et al.  C5A anaphylatoxin and its seven transmembrane-segment receptor. , 1994, Annual review of immunology.

[248]  E. Brown,et al.  Complement receptors and phagocytosis. , 1991, Current opinion in immunology.

[249]  T. Pozzan,et al.  Internalization pathway of C3b receptors in human neutrophils and its transmodulation by chemoattractant receptors stimulation. , 1991, Cell regulation.

[250]  H. Rosen,et al.  The leukocyte cell surface receptor(s) for the iC3b product of complement. , 1990, Current topics in microbiology and immunology.

[251]  M. Frank,et al.  Complement receptors. , 1981, Clinical immunology reviews.